Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 607-613

  Wiering, Bastiaan ^a   Ruers, Theo J M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Cryosurgery; FDG; Liver metastases; PET; Positron emission tomography; Radiofrequency ablation; Staging; Surgery; Therapy response monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CATHETER ABLATION; COLORECTAL CANCER; COLORECTAL SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER RESECTION; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 4444382132     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.607     Document Type: Review

References (54)

1. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br. J. Surg. 77, 1241-1246 (1990).
2. Gayowski TJ, Iwatsuki S, Madariaga JR et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116, 703-711 (1994).
3. Fong Y, Cohen AM, Fortner JG et al. Liver resection for colorectal metastases. J. Clin. Oncol. 15, 938-946 (1997).
4. Fortner J, Silva JS, Golbey RB et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer: I. Treatment by hepatic resection. Ann. Surg. 199, 306-316 (1984).
5. Gibbs JF, Weber TK, Rodriguez-Bigas MA et al. Intraoperative determinants of unresectability for patients with colorectal hepatic metastases. Cancer 82, 1244-1249 (1982).
6. Steele G, Bleday R, Mayer RJ. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J. Clin. Oncol. 9, 1105-1112 (1991).
7. Scheele J, Stangl R, Altendorf-Hofmann A et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110, 13-29 (1991).
8. 18F]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J. Clin. Oncol. 15, 388-395 (2002).
9. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br. J. Surg. 81, 1666-1670 (1994).
10. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch. Surg. 131, 703-707 (1996).
11. Ogunbiyi OA, Flanagan FL, Dehtashti F et al. Detection of recurrent and metastatic colorectal cancer comparison of positron emission tomography and computed tomography. Ann. Surg. Oncol. 4, 613-620 (1997).
12. Abdel-Nabi H, Doerr RJ, Lamonica DM et al. Staging of primary colorectal carcinomas with fluorine-18-fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206, 755-759 (1998).
13. Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic carcinoma with PET. J. Nucl. Med. 38, 1196-1201 (1997).
14. Flamen P, Stroobants S, Van Cutsem E et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluorodeoxy-D-glucose in recurrent colorectal cancer. J. Clin. Oncol. 17, 894-901 (1999).
15. 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am. J. Surg. 178, 282-287 (1999).
16. Whiteford MH, Whiteford HM, Yee LF et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis. Colon Rectum. 43, 759-767 (2000).
17. Vitola JV, Delbeke D, Sandler MP et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am. J. Surg. 171, 21-26 (1996).
18. Boykin KN, Zibari GB, Lilien DL et al. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am. Surg. 65, 1183-1185 (1999).
19. Zhuang H, Sinha P, Pourdehnad M et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl. Med. Commun. 21, 793-798 (2000).
20. 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann. Oncol. 9, 397-401 (1998).
21. Yasuda M, Makuuchi Y, Sadahiro S et al. Colorectal cancer recurrence in the liver: detection by PET. Tokai J. Exp. Clin. Med. 23, 167-171 (1998).
22. Topal B, Flamen P, Aerts R et al. Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases. Eur. J. Surg. Oncol. 27, 175-179 (2001).
23. Rohren EM, Paulson EK, Hagge R et al. The role of F-18 positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin. Nucl. Med. 27, 550-555 (2002).
24. Rydzewski B, Dehdashti F, Gordon BA et al. Usefulness of interoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. Am. J. Roentgenol. 178, 353-358 (2002).
25. Delbeke D, Martin WH, Sandler MP et al. Evaluation of benign vs. malignant hepatic lesions with positron emission tomography. Arch. Surg. 133, 510-516 (1998).
26. Strasberg SM, Dehdashti F, Siegel BA et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann. Surg. 233, 293-299 (2001).
27. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RE Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224, 748-756 (2002).
28. Huebner RH, Park KC, Shepherd JE et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nucl. Med. 41, 1177-1189 (2000).
29. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J. R. Coll. Surg. Edinb. 43, 141-154 (1998).
30. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 6, 24-33 (2001).
31. Wood TT, Rose DM, Chung M et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations and complications. Ann. Surg. Oncol. 7, 593-600 (2000).
32. Ruers TI, Jager GJ, Wobbes T. Cryosurgery for colorectal liver metastases. Semin. Oncol. 27, 120-125 (2000).
33. Solbiati L, Ierace T, Tonolini M et al. Radiofrequency thermal ablation of hepatic metastases. Eur. J. Utrasound 13, 149-158 (2001).
34. Curley SA, Izzo F, Delrio P et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann. Surg. 230, 1-8 (1999).
35. Crews KA, Kuhn JA, McCarty TM et al. Cryosurgical ablation of hepatic tumors. Am. J. Surg. 174, 614-617 (1997).
36. Adam R, Akpinar E, Johann M et al. Place of cryosurgery in the treatment of malignant liver tumors. Ann. Surg. 225, 39-38 (1997).
37. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 167, 759-768 (1996).
38. Langenhoff BS, Oyen WJG, Jager GJ et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J. Clin. Oncol. 20, 4453-4458 (2002).
39. 18F]fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J. Surg. Oncol. 84, 215-223 (2003).
40. Anderson GS, Brinkmann F, Soulen MC et al. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin. Nucl. Med. 28, 192-197 (2003).
41. 18F]FDG PET a comparison with CT and MRI. Eur. J. Nucl. Med. Mol. Imaging 29, 815-820 (2002).
42. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J. Clin. Oncol. 14, 700-708 (1996).
43. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q. J. Nucl. Med. 47, 8-13 (2003).
44. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179, 765-770 (1991).
45. Nakamoto Y, Tatsumi M, Cohade C, Osman M, Marshall LT, Wahl RL. Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. Eur. J. Nucl. Med. Mol. Imaging 30, 597-602 (2003).
46. Hosten N, Kreissig R, Puls R et al. Fusion of CT and PET data: methods and clinical relevance for planning laser-induced thermotherapy of liver metastases. Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb. Verfahr. 172, 630-635 (2000).
47. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J. Nucl. Med. 45(Suppl. 1), 82S-95S (2004).
48. Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH. PET/CT: panacea, redundancy, or something in between? J. Nucl. Med. 45, 15S-24S (2004).
49. Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 29, 681-690 (2002).
50. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur. J. Nucl. Med. Mol. Imaging 30, 988-994 (2003 ).
51. Francis DL, Visvikis D, Costa DC et al. Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both (18)FDG and (18)FLT PET. Eur. J. Nucl. Med. Mol. Imaging (2004) (In Press).
52. Wester HJ, Brockmann J, Rosch F et al. PET-pharmacokinetics of (18)F-octreotide: a comparison with (67)Ga-DFO- and (86)Y-DTPA-octreotide. Nucl. Med. Biol. 24, 275-286 (1997).
53. 86Y-DOTA0)-D-phe1-TyR3-octreotide (SMT487) - a Phase I clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging 30, 510-518 (2003).
54. Hofmann M, Maecke H, Borner R et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28, 1751-1757 (2001).